文献速递神经肿瘤

安罗替尼靶向治疗伴PDGFR-α突变的H3K27M突变型弥漫性中线胶质瘤一例报告

Targeted therapy with anlotinib for a H3K27M mutation diffuse midline glioma patient with PDGFR-α mutation: a case report.
PubMed 文献 · Acta Neurochir (Wien) · 2021-11-23

本文报告一例成人多灶性H3K27M突变型弥漫性中线胶质瘤患者,伴PDGFR-α突变,接受多靶点酪氨酸激酶抑制剂安罗替尼治疗后获益,为这类患者提供了一种有前景的治疗选择。

要点

  • H3K27M突变型弥漫性中线胶质瘤是2016年WHO中枢神经系统肿瘤分类第四版修订中定义的新实体。
  • 安罗替尼是一种多靶点酪氨酸激酶抑制剂,此前未见用于H3K27M突变型弥漫性中线胶质瘤的报道。
  • 本文首次报告一例成人多灶性H3K27M突变型弥漫性中线胶质瘤患者从安罗替尼治疗中获益。

核心结论

  • 本文首次报告一例成人多灶性H3K27M突变型弥漫性中线胶质瘤患者从安罗替尼治疗中获益,为这类患者提供了一种有前景的治疗选择。

研究设计与样本

  • 病例报告:一例成人多灶性H3K27M突变型弥漫性中线胶质瘤患者,伴PDGFR-α突变。

主要发现

  • 该成人多灶性H3K27M突变型弥漫性中线胶质瘤患者接受安罗替尼治疗后获益。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

H3K27M-mutant diffuse midline glioma (H3K27M-mt DMG) was a novel entity, which was defined by K27M mutations in H3F3A or HIST1H3B/C in the 2016 WHO updated fourth edition of the central nervous system (CNS) tumor classification. There is an urgent need for effective therapeutic strategies. Anlotinib is a multitarget tyrosine kinase inhibitor, which has not been reported for H3K27M-mt DMG treatment. Here, we firstly reported an adult multifocal H3K27M-mt DMG patient benefiting from anlotinib. This report provides a promising treatment option for H3K27M-mt DMG patients.

来源:Acta Neurochir (Wien),查看原文。版权归原作者所有。

引用

  1. Wang Q, Niu W, Pan H, et al. Targeted therapy with anlotinib for a H3K27M mutation diffuse midline glioma patient with PDGFR-α mutation: a case report. Acta Neurochir (Wien). 2021. PMID: 34812950. doi:10.1007/s00701-021-05061-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。